R&D channel feed – Endpoints News

R&D channel feed

Nektar’s pitch on early cancer drug OK runs into a regulatory brick wall

8 years ago

Heartburn: Ironwood shares sink after blockbuster contender disappoints on a key goal in PhIIb

8 years ago

Researchers plot a course into PhIII after another Alzheimer’s drug flunks a key test

8 years ago

Eli Lilly buys itself an antibody R&D platform from Tillman Gerngross’s Adimab

8 years ago

Paratek goes 3-for-3 in PhIII, but antibiotic stumbles on side effect profile

8 years ago

Back from the dead: Nektar hunts a blockbuster deal as opioid '181 looks less addictive than oxy

8 years ago

King cancer: The top 10 therapeutic areas in biopharma R&D

8 years ago

CymaBay shares get a bounce on positive PBC PhII data

8 years ago

FDA's Scott Gottlieb is fielding a new team of recruiters to start scouting top talent

8 years ago

FDA embraces the first US application for a gene therapy, offering an accelerated test case

8 years ago

FDA advisers back Novartis’ game-changing personalized CAR-T for cancer, approval in sight

8 years ago

D-day: Novartis arrives at a crossroad in the blockbuster race to win the first FDA OK for CAR-T

8 years ago

BioMarin lays out its PhIII strategy for its closely-watched gene therapy for hemophilia A

8 years ago

Arena takes a big step down the comeback trail with PhII success, shares rocket up

8 years ago

FDA orders a rare retreat on Amicus’ migalastat, dropping PhIII demand and signaling a major shift for drug developers

8 years ago

Pioneering gene therapy patients stay on track, boosting Spark’s hemophilia B program

8 years ago

Alnylam, Sanofi flag another promising step forward for PhIII hemophilia drug

8 years ago

FDA raises big safety issues in Novartis’ CAR-T review, but spotlights post-marketing path forward

8 years ago

Inotek shares crater (again) as another glaucoma drug study flops

8 years ago

Troubled by deaths, FDA orders Merck to slam the brakes on three Keytruda studies

8 years ago

Personalized cancer vaccines stake their claim to the next frontier in immuno-oncology

8 years ago

Bristol-Myers’ tarnished checkpoint star Opdivo beats out Yervoy in surprise PhIII

8 years ago

Far from the big hubs, Apellis is steering its rival to Alexion's Soliris into a PhIII program

8 years ago

Alkermes claims a success in PhIII schizophrenia head-to-head, but where’s the benefit for patients?

8 years ago

First page Previous page 295 296 297298299 300 301 Next page Last page